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Abstract 
We report the detailed long-term reconstitu-
tion of B-lymphocyte subpopulations, immuno  -
globulins, and specific antibody production after
two courses of rituximab in a young, previously
healthy  girl  with  steroid-dependent  autoim-
mune hemolytic anemia. B-lymphocyte subpop-
ulations were surprisingly normal directly after
reconstitution.  However,  there  was  a  slower
reconstitution  after  the  second  rituximab
course, especially of non-switched and switched
memory B-lymphocytes, and a temporary decline
in IgM below age-matched reference values.
Introduction
Rituximab is increasingly used in the treat-
ment  of  various  hematological  malignancies
and, more recently, autoimmune diseases like
autoimmune  hemolytic  anemia  (AIHA).1
Rituximab is a monoclonal antibody that reacts
with the CD20 antigen, which is expressed on
pre-B and mature B-lymphocytes, but not on
plasma cells. B-lymphocytes play an important
regulatory and potentially pathogenic role in
autoimmune diseases through antibody-inde-
pendent  mechanisms  like  antigen  presenta-
tion, T-lymphocyte activation, and the produc-
tion of cytokines and chemokines.2,3 They are
also the precursors of (auto)antibody-produc-
ing plasma cells. Depletion of B-lymphocytes is
therefore likely to interfere with the complex
(auto)immune process, but the exact mecha-
nism of its effect on autoimmune diseases is
not yet fully understood.4
Treatment with rituximab results in a rapid
and  sustained  depletion  of  B-lymphocytes.
There are detailed reports on the rate and phe-
notype of B-lymphocyte subpopulation recovery
after rituximab treatment in adults:5-12 after B-
cell depletion immature B-lymphocytes reap-
pear  first,  followed  by  naïve  B-lymphocytes;
CD27+ memory  B-lymphocytes  may  remain
reduced up to 2 years after rituximab treat-
ment.5,8
It would be expected that depletion of CD20+
B-lymphocytes has direct effects on antibody
production,  and  indirect  effects  on  cellular
immunity.  Indeed,  hypogammaglobulinemia
requiring substitution was recently described
in a child with repeated rituximab treatment
for idiopathic thrombocytopenic purpura and
underlying  autoimmune  lymphoproliferative
disease.13However, until now large numbers of
serious infectious complications of rituximab
treatment have not been described,4 perhaps
because antibody-producing plasma cells are
spared.
In this paper, we give a detailed description
of the reconstitution of B-lymphocyte subpopu-
lations,  immunoglobulins  (Igs),  and  specific
antibody production after repeated treatment
with rituximab in a young, previously healthy,
girl with steroid-dependent AIHA.
Materials and Methods
Patient
In  August  2004,  a  previously  healthy  13-
months-old girl presented in our hospital with
AIHA which turned out to be steroid-depend-
ent. Aspecific IgG autoantibodies were strong-
ly positive. In August 2005, she was treated
with rituximab (4ﾥ375 mg/m2, 1 week apart).
Human  anti-chimeric  antibodies  (HACAs)
were  measured  once  and  found  negative.
Subsequently,  steroids  could  be  tapered  and
stopped  11  months  after  the  first  rituximab
treatment, in July 2006. A few weeks later, she
suffered a relapse and steroids were restarted,
and a second course with 4 gifts of rituximab
(375 mg/m2, 1 week apart) was administered.
Hereafter, the steroid dose was slowly reduced
again, and 11 months after the second treat-
ment with rituximab, in July 2007, at the age of
4 years, steroids were stopped completely. In
2011, at almost 8 years of age, there were still
no signs of relapse. Aspecific IgG autoantibod-
ies remained negative. She did not suffer from
any significant infections. The clinical course
of this girl is illustrated in Figure 1.
Preceding  rituximab  treatment,  but  while
on steroids, vaccination status was optimised
using  Prevenar  twice  (Wyeth)  followed  by
Pneumovax (Sanofi Pasteur MSD) for S. pneu-
moniae,  and  NeisVacC  (Baxter)  and
MeningovaxAC  (Sanofi  Pasteur  MSD)  for  S.
meningitidis. This was considered important,
because both rituximab and prolonged steroid
treatment might compromise immunity. After
2.5  years,  Pneumovax  and  Mencevax  ACWY
(Glaxo Smith Kline) vaccinations were given.
Diphtheria - tetanus - inactivated poliomyelitis
(DTP-NVI) vaccination was given at the age of
four, according to the regular Dutch immuni-
sation schedule (Figure 1).
Peripheral blood samples were taken at mul-
tiple time points (t = 0, 8, 14, 21, 56, 110, 202,
321, 383, 396, 403, 410, 417, 446, 530, 614, 718,
816, 1085 days after the first rituximab dose,
indicated with arrows in Figure 1) to establish
the reconstitution of B-lymphocyte subpopula-
tions, Ig titers and specific antibody production.
Immunophenotyping
Four-color  flow  cytometric  immunopheno-
typing was performed using the lyse and wash
whole-blood method. Aliquots of ethylene di-
aminetetra-acetic (EDTA) blood (50 ʼL) were
incubated for 15 min at room temperature in
the dark with the following monoclonal anti-
bodies: isotype control gamma 1 conjugated to
fluorescein  isothiocyanate  (FITC)  (Becton
Dickinson, San Jose, CA, USA (BD)), isotype
control gamma 2a conjugated to phycoerythrin
(PE)  (BD),  CD3-FITC  (Immuno  Quality
Products, Groningen, The Netherlands (IQP)),
CD3  conjugated  to  allophycocyanin  (APC)
(BD), CD3 conjugated to PE-Cyanin5 (PE-Cy5)
(Coulter Immunotech, Marseille, France (CI)),
CD4-PE  (IQP),  CD4-PE-Cy5  (CI),  CD5-FITC
(BD), CD8-PE (IQP), CD8 conjugated to peri-
dinin chlorophyll protein cyanin 5.5 (PerCP-
Cy5.5)  (BD),  CD10-APC  (BD),  CD16/56-PE
(BD),  CD19-PE  (BD),  CD19-PE-Cy5  (CI),
CD19-PerCP-Cy5.5  (BD),  CD20-FITC  (BD),
CD21-PE  (BD),  CD25-FITC  (CI),  CD27-FITC
(BD),  CD27-PE  (BD),  CD45RA-PE  (CI),
CD45RO-FITC  (BD  or  IQP),  IgD-FITC
(SouthernBiotech,  Birmingham,  USA),  and
IgM-FITC  (Sanofi  Pasteur  Marnes-La-
Coquette, France). To eliminate immunoglobu-
lins, aliquots destined for anti-IgM and anti-
IgD were washed three times before staining.
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Erythrocytes  were  lysed  using  FACSLysing
solution (BD) according to the manufacturer’s
protocol.  The  cells  were  washed  twice  with
0.5%  bovine  serum  albumin/phosphate-
buffered saline. Analysis was performed using
CellQuest ProSoftware (BD) on a FACSCalibur
flowcytometer  (BD),  which  was  calibrated
according to the guidelines of Kraan et al.14
The  absolute  leukocyte  count  (ﾥ109/L)  was
determined on a Sysmex XE-2100 hematology
analyzer (Sysmex, Kobe, Japan). The absolute
number (ﾥ109/L) of a lymphocyte subpopula-
tion was calculated by multiplying the calculat-
ed absolute lymphocyte size (ﾥ109/L) with the
relative size of the lymphocyte subpopulation
(%)  within  the  lymphocyte  gate.  The  values
were compared to reference values in healthy
children derived from our laboratory.
Immunoglobulins
IgG,  IgA,  IgM,  and  IgG-subclasses  were
determined by standard nephelometric meth-
ods  (BNProspec,  Dade  Behring,  The
Netherlands). Specific antibody responses to
pneumococcal vaccination were determined by
ELISA, diphtheria and tetanus antitoxin anti-
bodies  with  a  toxin-binding  inhibition
assay.15,16
Results
As expected, all peripheral blood B-lympho-
cyte subpopulations disappeared rapidly upon
treatment  with  rituximab  (Figure  2),  T-lym-
phocyte  subpopulation  and  NK-cell  counts
were not affected (Table 1). After the first rit-
uximab course, B-cells reappeared at t = 110
days, after the second course they reappeared
later, at t = 614 (218 days after the second rit-
uximab course). The reappearing cells were
mainly naive cells (CD19+IgD+CD27-), around
one third were CD5+ (Figure 2). After the sec-
ond  course,  both  non-switched
(CD19+IgD+CD27+) and switched (CD19+IgD-
CD27+)  memory  B-lymphocytes  reappeared
later than after the first course (at t = 110 days
after the first course, together with the naive
cells, and at 320 days after the second course,
which is 102 days after the first naive cells, at
t  =  718  days  (Figure  2).  However,  switched
memory B-lymphocytes were within the age-
limits of normal from the moment they reap-
peared (Table 1). CD21+ cells (IgM- and IgM+)
repopulated in the same manner as the other
B-lymphocyte subpopulations.
IgG, IgA, and IgG-subclass levels were unaf-
fected by the rituximab treatment (Table 1),
but  after  the  second  course  a  temporary
decrease in IgM was found (0.48 g/l at t = 446
days; 0.23 g/l at t = 530 days; 0,6 g/l at t = 614
days), as has been described before.17,18 After
both  rituximab  treatments  prednisone  was
used every other day and slowly tapered until it
could be stopped. After the first treatment with
rituximab the dosage of prednisone was slight-
ly higher. During that time we didn’t see an
effect  on  immunoglobulins  or  significant
infections.  Vaccination  responses  before  the
first  rituximab  course  were  normal;  booster
responses after the second course (after t =
1085  days)  were  normal  as  well  (Table  1),
despite the fact that she had been on steroids
during the first round of vaccinations.
Discussion
We followed a girl with steroid-dependent
AIHA who was treated with 4 gifts of rituximab
twice. She repopulated mainly with naive B-
lymphocytes, around one third CD5+, as could
be expected for her age. Interestingly, her B-
lymphocytes  returned  to  normal  faster  than
described  before  in  both  adults5-7 and  chil-
dren,17,18 but  these  children  had  underlying
diseases that may have influenced the recon-
stitution.  She  did  not  suffer  any  significant
infections, and responded well to vaccination,
despite her prolonged steroid use.
During repopulation memory B-lymphocytes
peaked just before the relapse in our patient.
Increasingly, early relapse of autoimmune dis-
eases  like  rheumatoid  arthritis  or  SLE  are
reported in adult patients with a higher num-
ber of memory B-lymphocytes in early reconsti-
tution in comparison to patients with later or
no  relapse.5,8,10 Our  case  suggests  that  this
relation may also exist in children.
After the second rituximab treatment, the
reconstitution  was  somewhat  slower  in  our
patient. This has been described by others,4,13
suggesting  that  multiple  rituximab  courses
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Table 1. Absolute values of lymphocyte subpopulations in comparison with control values from healthy age-matched children.
time in days t=0 t=110 t=396 t=614 t=718
CD19+ 0.86* 0.34 0.54 0.33 0.54
total B-lymphocytes 0.76 (0.3-2.8)** 0.76 (0.3-2.8) 0.49 (0.3-0.7) 0.49 (0.3-0.7) 0.49 (0.3-0.7)
CD19+CD5+ 0.54  0.14 0.08 0.038 0.16
CD5+B-lymphocytes 0.39 (0.1-1.3) 0.39 (0.1-1.3) 0.15 (0.0-0.4) 0.15 (0.0-0.4) 0.15 (0.0-0.4)
CD19+CD10+ 0.18 0.07 0.48 0.33 0.13
Immature B-lymphocytes 0.24 (0.09-0.87) 0.24 (0.09-0.87) 0.12 (0.04-0.25) 0.12 (0.04-0.25) 0.12 (0.04-0.25)
CD19+IgD+CD27- 0.74 0.28 0.36 0.30 0.47
naive B-lymphocytes 0.61 (0.24-2.61) 0.61 (0.24-2.61) 0.37 (0.20-0.59) 0.37 (0.20-0.59) 0.37 (0.20-0.59)
CD19+IgD+CD27+ 0.06 0.01 0.08 0.013 0.027
non-switched memory
B-lymphocytes 0.04 (0.01-0.12) 0.04 (0.01-0.12) 0.04 (0.02-0.1) 0.04 (0.02-0.1) 0.04 (0.02-0.1)
CD19+IgD-CD27+ 0.05 0.04 0.072 0.086 0.032
switched memory
B-lymphocytes 0.022 (0.005-0.03) 0.022 (0.005-0.03) 0.040 (0.012-0.13) 0.040 (0.012-0.13) 0.040 (0.012-0.13)
CD3+cells 2.79 2.64 1.11 2.58 2.12
(T lymphocytes) 2.5 (0.7-8.8) 1.9 (0.85-4.3) 1.9 (0.85-4.3) 1.9 (0.85-4.3)
NK cells 0.28 0.18 0.44 0.32 0.24
0.47 (0.055-4.0) 0.18 (0.061-0.51) 0.18 (0.061-0.51) 0.18 (0.061-0.51)
IgG*** 5.8 6.2 8.6 5.9 7.2
IgA*** 0.52 0.68 0.92 0.88 1.23
IgM*** 1.07 0.65 1.56 0.6 0,54
*Value in patient in 109/l. **Median (range) of healthy age-matched controls in 109/l. t = 0: start of first rituximab course; t = 396: start of second rituximab course; t=614: start of recovery after second rituximab course;
t = 718: full recovery of all B-lymphocyte subpopulations. ***Immunoglobulins in g/L.[Pediatric Reports 2011; 3:e28] [page 113]
may eventually lead to secondary antibody defi-
ciency  and  infectious  complications.  Future
studies in larger numbers of children are need-
ed to analyze this further. 
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Figure 2. B-lymphocyte subpopulations. Timeline starts in August 2005, directly after
first rituximab treatment, shows depletion after 2nd rituximab treatment and continues
until roughly 2.5 years remission. Total B-lymphocytes (CD19+) bold line; naive B-lym-
phocytes  (CD19+IgD+CD27-)  narrow  line.  Switched  memory  B-lymphocytes
(CD19+IgD-CD27+)  score-dot-dot;  non-switched  memory  B-lymphocytes
(CD19+IgD+CD27+) interrupted line; CD5+ B-lymphocytes dotted line. Reference values
determined in healthy children in our laboratory are shown as vertical lines.
Figure  1.  Time  schedule  of  patient’s  history.  Dotted  line:  hemoglobin  (mmol/L).
Prednisone (mg/kg/day) uninterrupted line; prednisone (mg/kg every other day) inter-
rupted line. Arrows: *rituximab treatment; ** blood sample (resp t = 0, 8, 14, 21, 56, 110,
202, 321, 383, 396, 403, 410, 418, 446, 530, 614, 718, 817, 1085 days after the first rit-
uximab dose); # vaccination. a: first presentation with autoimmune hemolytic anemia
(August 2004); b: first treatment with rituximab (August 2005); c: recovery of B-lympho-
cytes (day 110 after first rituximab treatment); d: relapse and second treatment with rit-
uximab (July 2006); e: recovery of B-lymphocytes (day 218 after 2nd rituximab treat-
ment). Timeline stops in July 2007 when steroids are stopped.